Mouse embryonic stem cells differentiated into motor neurons after a GFP tag was inserted in frame with the motor-neuron-specific transcription factor HB9, using CRISPR/Cas9 engineering. The Patent ...

The U.S. Patent and Trademark Office issued Caribou Biosciences, a startup co-founded by UC Berkeley researcher Jennifer Doudna, intellectual property rights for developments in CRISPR gene-editing ...

Biochemist Jennifer Doudna, a faculty scientist at the Department of Energy’s Lawrence Berkeley National Laboratory, founder of the Innovative Genomics Institute, and a professor at UC Berkeley, has ...

At the Healthcare Analytics Summit™ 2024 (HAS® 24), Jennifer Doudna, PhD, of the University of California, Berkeley, sat down with Melissa Welch, MD, MPH, President of Welch Perspectives Healthcare ...

UC Berkeley and Cambridge, Mass.-based Broad Institute are in the midst of a years-long legal battle over whose researchers own the rights to CRISPR-Cas9 gene editing technology — a dispute with roots ...

In layman’s terms, CRISPR allows a scientist to make incredibly precise cuts inside a gene very quickly, slashing hours from genomic research. Since discovering the technique, Doudna and Charpentier ...

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its second Japanese Patent ...

In 2020, Jennifer Doudna, Ph.D., received the Nobel Prize in Chemistry, CRISPR-Cas9, a method for genome editing. Often referred to as “molecular scissors,” CRISPR cuts DNA at specific locations that ...

UCSB Arts & Lectures and the Cancer Foundation of Santa Barbara co-present Dr. Jennifer Doudna, CRISPR Gene Editing and the Future of Human Health on Tuesday, Oct. 22, at 7:30 p.m. at The Granada ...

Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, No. 2 (January 12, 2021), pp. 1-9 (9 pages) CRISPR-Cas9 from Streptococcus pyogenes is an RNA-guided DNA ...

Most approved gene therapies today, including those involving CRISPR-Cas9, work their magic on cells removed from the body, after which the edited cells are returned to the patient. This technique is ...